109. 非典型溶血性尿毒症症候群 Disease details / Clinical trials / Drug dev / DR info

ALN-CC5
   Alnylam Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2017-001082-24-SE   Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden
      2017   Phase 2   EUCTR2017-001082-24-LV   Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden
      2017   Phase 2   EUCTR2017-001082-24-LT   Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden
      2017   Phase 2   EUCTR2017-001082-24-EE   Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2019   Phase 2   EUCTR2018-004382-13-IT   Italy
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2017   Phase 3   EUCTR2016-002027-29-IT   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2017   Phase 3   EUCTR2016-002499-29-DE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002027-29-DE   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
   Alexion Pharmaceuticals Incorporated
      2019   Phase 3   EUCTR2016-002499-29-FR   Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-SE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-IT   Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-GB   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-ES   Spain;United States
      2017   Phase 3   EUCTR2016-002499-29-BE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-AT   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002027-29-SE   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002027-29-ES   Austria;Belgium;Czech Republic;Germany;Italy;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002027-29-BE   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002027-29-GB   Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002027-29-AT   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2016-002027-29-CZ   Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
ANTI-C5 antibody
   ALEXION PHARMACEUTICALS, INC.
      2013   Phase 2   EUCTR2010-020326-18-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   -   EUCTR2010-020326-18-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020326-18-BE   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-ES   Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2011   -   EUCTR2010-020310-28-DE   Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   -   EUCTR2010-020310-28-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2010   -   EUCTR2010-020326-18-GB   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-020326-18-DE   Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-020310-28-AT   Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-006955-28-SE   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-NL   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006955-28-GB   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-DE   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-AT   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-SE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-NL   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006954-17-GB   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-FR   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-DE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-AT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-SE   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-NL   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006953-41-GB   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-DE   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006953-41-AT   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-SE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-NL   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006952-23-GB   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006952-23-FR   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-DE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-AT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      -   Phase 2   EUCTR2010-020310-28-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
C5 INH MAB, SKY59, RO/CH7092230
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-002475-35-IT   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002437-15-IT   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-002475-35-PL   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-HU   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-FR   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-DE   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-BE   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2022   Phase 3   EUCTR2020-002437-15-HU   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
      2022   Phase 3   EUCTR2020-002437-15-BE   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
      2021   Phase 3   EUCTR2020-002437-15-PL   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-002437-15-ES   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
CCX168
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2015   Phase 2   EUCTR2014-004261-24-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2015   Phase 2   NCT02464891   Italy
Cemdisiran
   Alnylam Pharmaceuticals
      2017   Phase 2   NCT03303313   Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Moldova, Republic of;Serbia;Sweden
   Alnylam Pharmaceuticals, Inc.
      2017   Phase 2   EUCTR2017-001082-24-SE   Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden
      2017   Phase 2   EUCTR2017-001082-24-LV   Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden
      2017   Phase 2   EUCTR2017-001082-24-LT   Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden
      2017   Phase 2   EUCTR2017-001082-24-EE   Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2019   Phase 2   EUCTR2018-004382-13-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2021   Phase 2   NCT03999840   Italy
Coversin
   Akari Therapeutics Plc
      2019   Phase 3   EUCTR2016-004129-18-LT   Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
      2018   Phase 3   EUCTR2016-004129-18-NL   Argentina;Lithuania;Netherlands;Poland;United Kingdom
      2017   Phase 3   EUCTR2016-004129-18-PL   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
Crovalimab
   Camelia Sima
      2022   Phase 3   JPRN-jRCT2031210061   BELGIUM;BRAZIL;CANADA;CHINA;FRANCE;GERMANY;HUNGARY;ISRAEL;ITALY;Japan;MEXICO;PERU;POLAND;SOUTH AFRICA;SPAIN;TURKEY;UNITED STATES
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-002475-35-IT   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002437-15-IT   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-002475-35-PL   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-HU   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-FR   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-DE   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-BE   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2022   Phase 3   EUCTR2020-002437-15-HU   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
      2022   Phase 3   EUCTR2020-002437-15-BE   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
      2021   Phase 3   EUCTR2020-002437-15-PL   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   Hoffmann-La Roche
      2021   Phase 3   NCT04958265   Belgium;Brazil;Canada;China;France;Hungary;India;Israel;Italy;Japan;Mexico;Poland;South Africa;Spain;United States
      2021   Phase 3   NCT04861259   Belgium;Brazil;Canada;China;France;Germany;Hungary;India;Israel;Italy;Japan;Mexico;New Zealand;Peru;Poland;South Africa;Spain;Turkey;United States
   Mona D. Shah
      2022   Phase 3   JPRN-jRCT2041210086   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-002437-15-ES   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
Eculizumab
   ALEXION PHARMACEUTICALS
      2011   -   EUCTR2010-020310-28-IT   Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-006955-28-IT   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-IT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-IT   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-IT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   ALEXION PHARMACEUTICALS INCORPORATED
      -   Phase 4   EUCTR2015-003135-35-IT   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Norway;Poland;Russian Federation;Spain;United Arab Emirates;United Kingdom;United States
   ALEXION PHARMACEUTICALS, INC.
      2013   Phase 2   EUCTR2010-020326-18-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   -   EUCTR2010-020326-18-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020326-18-ES   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020326-18-BE   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-ES   Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2011   -   EUCTR2010-020310-28-DE   Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   -   EUCTR2010-020310-28-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2010   -   EUCTR2010-020326-18-GB   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-020326-18-DE   Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-020310-28-AT   Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-006955-28-SE   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-NL   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006955-28-GB   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-ES   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-DE   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-AT   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-SE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-NL   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006954-17-GB   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-FR   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-ES   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-DE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-AT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-SE   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-NL   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006953-41-GB   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-DE   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006953-41-AT   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-SE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-NL   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006952-23-GB   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006952-23-FR   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-ES   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-DE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-AT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      -   Phase 2   EUCTR2010-020310-28-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
   ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP)
      2023   Phase 3   EUCTR2022-002329-84-FR   France
   Alexion Pharmaceuticals
      2015   -   NCT02614898   Australia;Germany;United Kingdom;United States
      2012   Phase 2   NCT01757431   Japan
      2010   Phase 2   NCT01194973   Belgium;France;Germany;Italy;Spain;United Kingdom;United States
      2010   Phase 2   NCT01193348   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States
      2009   Phase 2   NCT00844844   Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2009   Phase 2   NCT00844545   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2009   Phase 2   NCT00844428   Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2009   Phase 2   NCT00838513   Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2023   Phase 3   NCT05876351   China
      2016   Phase 4   EUCTR2015-003135-35-DE   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Norway;Poland;Russian Federation;Spain;United Arab Emirates;United Kingdom;United States
   Children's Hospital Medical Center, Cincinnati
      2018   Phase 2   NCT03518203   United States
   HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL
      2019   Phase 4   EUCTR2019-001619-21-ES   Spain
   Nantes University Hospital
      2015   Phase 4   NCT02574403   France
   Newcastle Upon Tyne Hospitals NHS Foundation Trust
      2018   Phase 2   EUCTR2017-003916-37-GB   United Kingdom
FC- and CDR-modified humanised monoclonal antibody against C5
   ALEXION PHARMACEUTICALS INCORPORATED
      2017   Phase 3   EUCTR2016-002027-29-IT   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2017   Phase 3   EUCTR2016-002499-29-DE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
   Alexion Pharmaceuticals Incorporated
      2019   Phase 3   EUCTR2016-002499-29-FR   Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-SE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-IT   Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-GB   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-ES   Spain;United States
      2017   Phase 3   EUCTR2016-002499-29-BE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-AT   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002027-29-SE   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002027-29-BE   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002027-29-AT   Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2016-002027-29-CZ   Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States
Iptacopan
   Iwasaki Ryohei
      2024   Phase 3   JPRN-jRCT2031230686   China;France;Germany;Italy;Japan;Spain;Turkey;United Kingdom;United Status
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-005186-13-SK   Austria;Brazil;China;Czech Republic;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovakia;Slovenia;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005186-13-CZ   Austria;Brazil;China;Czech Republic;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovakia;Slovenia;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005186-13-AT   Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovenia;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2024   Phase 3   NCT05935215   China;Japan;Spain;Turkey;United Kingdom
      2022   Phase 3   NCT04889430   Austria;Brazil;China;Czechia;Greece;India;Japan;Korea, Republic of;Slovakia;Slovenia;Taiwan;United Kingdom;United States
Iptacopan hydrochloride
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-005186-13-SI   Austria;Brazil;China;Czech Republic;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovakia;Slovenia;Taiwan;United Kingdom;United States
Iptcaopan 200 MG
   Novartis Pharmaceuticals
      2024   Phase 3   NCT05795140   Brazil;China;Czechia;India
LNP023
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-005186-13-SK   Austria;Brazil;China;Czech Republic;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovakia;Slovenia;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005186-13-SI   Austria;Brazil;China;Czech Republic;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovakia;Slovenia;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005186-13-CZ   Austria;Brazil;China;Czech Republic;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovakia;Slovenia;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005186-13-AT   Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovenia;Taiwan;United Kingdom;United States
NM8074
   NovelMed Therapeutics
      2025   Phase 2   NCT05684159   -
OMS00620646, OMS620646, MASP-2 antibody
   Omeros Corporation
      2018   Phase 3   EUCTR2017-002057-11-PL   Lithuania;Poland;Taiwan;United States
      2017   Phase 3   EUCTR2017-002057-11-LT   Lithuania;Poland;Taiwan;United States
OMS721
   Omeros Corporation
      2017   Phase 3   NCT03205995   United States
OMS721 100 MG/ML injection solution, OMS00620646, OMS620646, MASP-2 antibody
   OMEROS CORPORATION
      -   Phase 2   EUCTR2014-001032-11-IT   Belarus;Belgium;Bulgaria;Czechia;Germany;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
   Omeros Corporation
      2014   Phase 2   EUCTR2014-001032-11-PL   Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States
      2014   Phase 2   EUCTR2014-001032-11-LT   Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States
      2014   Phase 2   EUCTR2014-001032-11-BE   Belarus;Belgium;Bulgaria;Germany;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States
OMS721 185 MG/ML injection solution, OMS00620646, OMS620646, MASP-2 antibody
   Omeros Corporation
      2014   Phase 2   EUCTR2014-001032-11-PL   Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States
      2014   Phase 2   EUCTR2014-001032-11-LT   Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States
OMS721 drug product 185 MG/ML
   Omeros Corporation
      2018   Phase 3   EUCTR2017-002057-11-PL   Lithuania;Poland;Taiwan;United States
      2017   Phase 3   EUCTR2017-002057-11-LT   Lithuania;Poland;Taiwan;United States
Ravulizumab
   Alexion
      2017   Phase 3   NCT02949128   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Taiwan;United Kingdom;United States
   Alexion Pharmaceuticals Inc.
      2017   Phase 3   EUCTR2016-002499-29-DE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
   Alexion Pharmaceuticals Incorporated
      2017   Phase 3   EUCTR2016-002499-29-SE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-GB   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-BE   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002499-29-AT   Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2017   Phase 3   NCT03131219   Belgium;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States
RO7112689/F03-01
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-002437-15-IT   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   F.Hoffmann-La Roche Ltd
      2022   Phase 3   EUCTR2020-002437-15-HU   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
      2022   Phase 3   EUCTR2020-002437-15-BE   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
      2021   Phase 3   EUCTR2020-002437-15-PL   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-002437-15-ES   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
RO7112689/F03-10
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-002475-35-IT   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002437-15-IT   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-002475-35-PL   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-HU   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-FR   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-DE   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2020-002475-35-BE   Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States
   F.Hoffmann-La Roche Ltd
      2022   Phase 3   EUCTR2020-002437-15-HU   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
      2022   Phase 3   EUCTR2020-002437-15-BE   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
      2021   Phase 3   EUCTR2020-002437-15-PL   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
   Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-002437-15-ES   Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States
RVA576
   Akari Therapeutics Plc
      2019   Phase 3   EUCTR2016-004129-18-LT   Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
      2018   Phase 3   EUCTR2016-004129-18-NL   Argentina;Lithuania;Netherlands;Poland;United Kingdom
      2017   Phase 3   EUCTR2016-004129-18-PL   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
      2017   Phase 3   EUCTR2016-004129-18-GB   Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom
Solaris
   Newcastle Upon Tyne Hospitals NHS Foundation Trust
      2018   Phase 2   EUCTR2017-003916-37-GB   United Kingdom
Soliris
   ALEXION PHARMACEUTICALS
      2011   -   EUCTR2010-020326-18-IT   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-006955-28-IT   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-IT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-IT   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-IT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
   ALEXION PHARMACEUTICALS INCORPORATED
      -   Phase 4   EUCTR2015-003135-35-IT   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Norway;Poland;Russian Federation;Spain;United Arab Emirates;United Kingdom;United States
   ALEXION PHARMACEUTICALS, INC.
      2013   Phase 2   EUCTR2010-020326-18-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   -   EUCTR2010-020326-18-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020326-18-BE   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-NL   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-GB   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   Phase 2   EUCTR2010-020310-28-ES   Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2011   -   EUCTR2010-020310-28-DE   Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2011   -   EUCTR2010-020310-28-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2010   -   EUCTR2010-020326-18-GB   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-020326-18-DE   Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2010-020310-28-AT   Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-006955-28-SE   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-NL   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006955-28-GB   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-DE   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006955-28-AT   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-SE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-NL   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006954-17-GB   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-FR   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-DE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-AT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-SE   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-NL   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006953-41-GB   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006953-41-DE   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006953-41-AT   Austria;Germany;Italy;Netherlands;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-SE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-NL   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006952-23-GB   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   Phase 2   EUCTR2008-006952-23-FR   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-DE   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-AT   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      -   Phase 2   EUCTR2010-020310-28-FR   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
   Alexion Pharmaceuticals, Inc.
      2016   Phase 4   EUCTR2015-003135-35-DE   Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Norway;Poland;Russian Federation;Spain;United Arab Emirates;United Kingdom;United States
   HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL
      2019   Phase 4   EUCTR2019-001619-21-ES   Spain
Soliris 300 MG concentrado para solucióN para perfusióN
   ALEXION PHARMACEUTICALS, INC.
      2011   Phase 2   EUCTR2010-020326-18-ES   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2008-006955-28-ES   Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006954-17-ES   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
      2009   -   EUCTR2008-006952-23-ES   Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Soliris 300 MG solution à diluer pour perfusion
   ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP)
      2023   Phase 3   EUCTR2022-002329-84-FR   France
Ultomiris
   Alexion Pharmaceuticals, Inc.
      2024   -   NCT06312644   United States